NCT05494762 2025-05-01Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsBeiGenePhase 1 Terminated55 enrolled